GSK flags up pipeline as HIV drugs help it beat profit forecasts

A jogger runs past a signage for pharmaceutical giant GlaxoSmithKline in LondonGlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. Strong sales of Tivicay and Triumeq validated GSK's decision in May to keep its HIV business, rather than spinning it off, and offset a further slide in revenue from lung drug Advair and lower group profit margins following a major business overhaul. The drugmaker recently sold its marketed cancer drugs to Novartis and bought the Swiss group's vaccines, while increasing its consumer health business through a joint venture.



Sexual Health News Headlines – Yahoo! News